Muñoz, Juan J. A. M.
Dariolli, Rafael
da Silva, Caio Mateus
Neri, Elida A.
Valadão, Iuri C.
Turaça, Lauro Thiago
Lima, Vanessa M.
de Carvalho, Mariana Lombardi Peres
Velho, Mariliza R.
Sobie, Eric A.
Krieger, Jose E.
Funding for this research was provided by:
Fundação de Amparo à Pesquisa do Estado de São Paulo (2013/17368-0, 2015/50216-5, 2014/24577-8, 2016/07541-5)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (465586/2014-7, 309179/2013-0, 442643/2020-9, 150397/2017-8)
Article History
Received: 22 March 2022
Accepted: 14 August 2022
First Online: 2 September 2022
Declarations
:
: For commercial cell line TROPO-GFP, ethical approval is not applicable. The SS109 clone was approved by the Ethics Committee for the Analysis of Research Projects (CAPPesq), of University of São Paulo Medical School under nº 0055/11.
: Not applicable.
: RD was employee at PluriCell Biotech during part of the period in which the study was independently conducted and owns shares in the company. The other author(s) declare no competing interests.